I am pretty impressed with this. On another thread the challenge was put to Dayspring: Take a terminal cancer without any reasonable conventional alternatives, treat with 3-BP and do this with public disclosure. Surprisingly they accepted the challenge. It is not clear that the patient has agreed to these conditions, though perhaps more information will be provided in time.
True the Arizona clinic is on the pricey side, though it will be a great opportunity to clear the air about the effectiveness of 3-BP within the context of high quality American medicine. The patient on the funding site seems to have a very serious form of cancer (bile duct) with not encouraging opportunities for long term survival with conventional treatment. There are no obvious ethical arguments that would suggest this should not be done, though clear ethical arguments that it should be. This patient would be the first prospectively treated patient with 3-BP. Taking the best responding patients with 3-BP obscures more than reveals the truth. Even the published patient reports likely suffer from some publication bias. This patient report could be very informative. All the more so, as the clinical trial that was supposed to start with 3-BP has of yet not begun.
Another website noted that there are laws forbidding disclosure of patient records without patient consent.
Anyone interested in funding the cure for cancer? The big pharmas have avoided this for the last 14 years since this was discovered. If the people show an interest in it, perhaps the big pharmaceutical can put the research into this that it deserves and develop an optimized version of 3-Bromopyruvate.
Edited by mag1, 10 June 2015 - 03:48 AM.